ArticleJournal of global health2023
The impact of COVID-19 pandemic on reported tuberculosis incidence and mortality in China: An interrupted time series analysis.
Article in Journal of global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Epidemiological Distribution Characteristics of Tuberculosis Among Older Adults in Chongqing (2020-2024): Spatial-Temporal Analysis.JMIR public health and surveillance · 2026Article
- Impacts of relaxed mask policies on COVID-19 epidemics: a modeling study in South Korea.BMC infectious diseases · 2026Article
- Age-period-cohort analysis of pulmonary tuberculosis epidemiological trends from 2005 to 2024 and forecasts for 2035 in Sichuan Province, China.Frontiers in public health · 2026Article
- Article
- Isoniazid-rhodanine molecular hybrids: design, synthesis, antimycobacterial activity and computational validation.RSC advances · 2025Article
- Impact of COVID-19 pandemic, and the mediating role of hospital caseload and severity on mortality of hospitalised tuberculosis patients in Thailand.Global health research and policy · 2025Article
- Evaluating Tuberculosis and Drug Resistance in Serbia: A Ten-Year Experience from a Tertiary Center.Antibiotics (Basel, Switzerland) · 2025Article
- Epidemiological changes in tuberculosis and genotyping characteristics ofFrontiers in microbiology · 2025Review
- The temporal trend of tuberculosis burden in an aging population in China: a secondary data analysis from the GBD 2019.BMC pulmonary medicine · 2024Article
- Impact of COVID-19 on diagnosis of tuberculosis and tuberculosis infection in South America, Asia, and Africa.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Article
- Relationship between hospitalization from cannabis usage and pulmonary tuberculosis in Thailand from 2017 to 2022.PloS one · 2024Article
- Temporal disruption in tuberculosis incidence patterns during COVID-19: a time series analysis in China.PeerJ · 2024Article
- Trends in tuberculosis mortality among older adults in China, 2004-2021: a Joinpoint regression and age-period-cohort analysis.Frontiers in public health · 2024Article
- Spatiotemporal analysis of tuberculosis in the Hunan Province, China, 2014-2022.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The reported number of cases and deaths from common infectious diseases can change during major public health crises. We explored whether the coronavirus disease 2019 (COVID-19) had an impact on tuberculosis (TB) incidence and mortality in China based on routinely reported TB data. Methods: We used TB data used from the monthly national notifiable infectious disease reports in China from January 2015 to January 2023. Based on an interrupted time series (ITS) design, we applied Poisson and negative binomial regression models to assess the changes of reported TB incidence and mortality before and during the COVID-19 pandemic. Results: We found a significant and immediate decrease in the levels of both reported TB incidence (relative risk (RR) = 0.887; 95% confidence interval (CI) = 0.810-0.973) and mortality (RR = 0.448; 95% CI = 0.351-0.572) at the start of COVID-19 outbreak. During the pandemic, the slope of reported incidence decreased significantly (RR = 0.994; 95% CI = 0.989-0.999), while the slope of reported mortality increased sharply (RR = 1.032; 95% CI = 1.022-1.041) owing to an abrupt rise in reported mortality after January 2022. Conclusions: Both TB incidence and mortality decreased immediately at the start of the COVID-19 pandemic. Over a longer period, the COVID-19 pandemic had contributed to a sustained and more significant decrease in reported incidence, and a delayed but sharp increase in reported mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.